Conferences – REVIVE

About
The Experts
Webinars & Conferences
Blog
Resources
Forums
Talk to an expert
JOIN US
My account
- Logout

Loading...

Conferences
WEBINARS

View all our past webinars.

You are here:Home-Conferences

Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018) — Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018)
4 September 2018

Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018) — Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018)
4 September 2018

Coping with Preclinical Toxicology Challenges — Coping with Preclinical Toxicology Challenges
10 June 2018

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent? — Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?
22 April 2018

PK-PD in support of accelerated programmes: how much is enough? — PK-PD in support of accelerated programmes: how much is enough?
22 April 2018

US regulatory tools for expedited antibacterial development programmes — US regulatory tools for expedited antibacterial development programmes
22 April 2018

EU regulatory tools for expedited antibacterial development programmes — EU regulatory tools for expedited antibacterial development programmes
22 April 2018

Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP? — Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?
5 September 2017

How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls — How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls
5 September 2017

Clinical Microbiology for a Development Program — Clinical Microbiology for a Development Program
5 September 2017

Share

Facebook Twitter Linkedin Reddit Email

REVIVE Hub

REVIVE is a space for everybody with an interest in antimicrobial R&D.

Launched in 2016 by the WHO and DNDi, the Global Antibiotic Research & Development Partnership (GARDP) aims to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists, while endeavouring to ensure sustainable access. GARDP is currently operating within DNDi, which provides its governance.

Popular forum topics

Superiority vs. non-inferiority studies – can PK-PD bridge this gap?
Setting Up A 'Support' Service in Anti-Infectives
Immunomodulators
Plant extracts for pan-drug resistant bugs?

Latest forum posts

Medicare’s New Technology Add-on Payment (NTAP) program
Lung or thigh infection models for UTI/ABSSI indication
Route of administration for treatment vs. that for determining PK
MIC50 or MIC90 in PD calculations?

CONNECT

Facebook
Twitter
Instagram
LinkedIn
YouTube
RSS
Events

GARDP
DNDi

© All Rights Reserved

Privacy Policy | Terms of Use | Acceptable Use Policy | Cookie Policy

We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our cookie policy